From there, patients continue to inject a weekly maintenance dose
most patients benefit from knowing this upfront
Prevents the formation of aging
Tirzepatide for Type 2 Diabetes (Mounjaro) Initiated at 2.5 mg weekly (to build tolerance) Bumped to 5 mg after 4 weeks, then titrated by 2.5 mg every 4 weeks as needed Dose adjustment guided by glycemic control (HbA1c targets) and side effect tolerability Typically used alongside diet and exercise and can be combined with other diabetes medications excluding type 1 diabetes Tirzepatide for Obesity (Zepbound) Initiated similarly at 2.5 mg weekly Increased to 5 mg after 4 weeks, with potential further titrations every 4 weeks in 2.5 mg steps Recommended maintenance doses for weight loss are 5 mg, 10 mg, or 15 mg weekly Also indicated for moderate to severe obstructive sleep apnea (OSA) related to obesity, often with doses of 10 mg or 15 mg Prescribed alongside a reduced-calorie diet and increased physical activity Why Gradual Dose Increases Matter Gastrointestinal side effects (nausea, diarrhea, vomiting) are common during initiation and can be dose-limiting Slow titration allows for better medication tolerance and improved adherence Adjustments are based on individual response and tolerance, highlighting the importance of medically supervised care Special Considerations: Who Needs Careful Monitoring
This work suggests that despite Zns large acceptance for use in cases of diarrhea, more nuanced studies need to be performed to see if these Zn treatments are having off-target effects such as promoting AMR development or enhancing the speed with which it develops in the human gut
